Development and validation of a survival nomogram and calculator for male patients with metastatic castration-resistant prostate cancer treated with abiraterone acetate and/or enzalutamide
Abstract Background Despite the widespread availability of medication choices for metastatic castration-resistant prostate cancer (mCRPC), biomarkers to predict the efficacy of each mCRPC treatment have not yet been established. This study developed a prognostic nomogram and a calculator to predict...
Guardat en:
| Autors principals: | , , , , , , , , , , , , |
|---|---|
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
BMC
2023-03-01
|
| Col·lecció: | BMC Cancer |
| Matèries: | |
| Accés en línia: | https://doi.org/10.1186/s12885-023-10700-0 |
| Etiquetes: |
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|